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Abstract 34 
Maintaining healthcare for noncommunicable diseases (NCDs) is particularly important during the 35 
COVID-19 pandemic; however, diversion of resources to acute care, and physical distancing 36 
restrictions markedly affected management of NCDs. We aimed to assess the medication management 37 
practices in place for NCDs during the second wave of the COVID-19 pandemic across European 38 
countries. In December 2020, the European Network to Advance Best practices & technoLogy on 39 
medication adherencE (ENABLE) conducted a cross-sectional, web-based survey in 38 European and 40 
one non-European countries. Besides descriptive statistics of responses, nonparametric tests and 41 
generalized linear models were used to evaluate the impact on available NCD services of the number 42 
of COVID-19 cases and deaths per 100,000 inhabitants, and gross domestic product (GDP) per capita. 43 
Fifty-three collaborators from 39 countries completed the survey. In 35 (90%) countries face-to-face 44 
primary-care, and out-patient consultations were reduced during the COVID-19 pandemic. The 45 
mean±SD number of available forms of teleconsultation services in the public healthcare system was 46 
3±1.3. Electronic prescriptions were available in 36 (92%) countries. Online ordering and home 47 
delivery of prescription medication (avoiding pharmacy visits) were available in 18 (46%) and 26 48 
(67%) countries, respectively. In 20 (51%) countries our respondents were unaware of any national 49 
guidelines regarding maintaining medication availability for NCDs, nor advice for patients on how to 50 
ensure access to medication and adherence during the pandemic. Our results point to an urgent need 51 
for a paradigm shift in NCD-related healthcare services to assure the maintenance of chronic 52 
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Introduction 55 
Noncommunicable diseases (NCDs) are a major public health issue, responsible for 80% of all years 56 
lived with disability and 70% of all deaths worldwide (WHO, 2018a; IHME, 2020). However, because 57 
of the COVID-19 pandemic (WHO, 2020a), NCDs have not been the main priority for healthcare 58 
services during the last year, as COVID-19 infected more than 114 million individuals, with 2.5 million 59 
deaths worldwide (ECDC, 2021).  60 
Notably, the epidemics of COVID-19 and NCDs are closely interlinked. Patients with NCDs are more 61 
susceptible to severe and fatal COVID-19 infection (Sheldon and Wright, 2020; Clark et al., 2020; 62 
CDC COVID-19 Response Team, 2020; Noor and Islam, 2020). Conversely, COVID-19 negatively 63 
affects lifestyle habits (e.g., lower physical activity, increased tobacco use); indirectly increasing the 64 
risk of developing and progression of NCDs (Papachristou et al., 2020, Palmer et al., 2020). There is 65 
also a growing body of evidence that effective management of NCDs has a protective effect against 66 
COVID-19 infection, and its severity. For example, continuous statin use during the month prior to 67 
hospital admission for COVID-19 was associated with a lower risk of developing severe infection, and 68 
a faster time to recovery (Daniels et al., 2020).  69 
Although, the appropriate management of NCDs is important during the COVID-19 pandemic, the 70 
intensive focus on COVID-19 prevention and treatment, the lockdown and physical distancing 71 
restrictions affected NCD-related healthcare services adversely. In May 2020, World Health 72 
Organization (WHO) surveyed service delivery for NCDs across 155 countries (WHO, 2020b) and 73 
found that COVID-19 markedly affected NCD services in all regions and income groups. In three-74 
quarters of countries there was considerable disruption to NCD services (e.g., rehabilitation services, 75 
hypertension management, diabetes care, asthma services). To overcome disruption many countries 76 
adopted strategies such as telemedicine services to replace in-person consultations (61% of countries) 77 
or triage to identify priorities (64% of countries). 78 
The continuity of medication therapy is a cornerstone for the effective management of NCDs (Kluge 79 
et al., 2020; Böhm et al., 2013). Even before the COVID-19 pandemic, about 50% of people with long-80 
term conditions were non-adherent to their medication (WHO, 2003) with potential serious health 81 
consequences for individuals (Chowdhury et al., 2013). For example, non-adherence to endocrine 82 
therapies in breast cancer patients increases the risk of metastases, disease recurrence and mortality 83 
(Lee et al., 2019; Font et al., 2019). Assuring continuous access to medication is a prerequisite of 84 
appropriate adherence, which may be compromised by disruptions of healthcare services and physical 85 
distancing restrictions due to COVID-19 crisis. 86 
The European Network to Advance Best practices & technoLogy on medication adherencE (ENABLE; 87 
CA19132) is a 4-year research initiative across Europe funded by the European Cooperation in Science 88 
and Technology (COST) Action. ENABLE brings together researchers from 39 countries, among 89 
others, with the objective to evaluate current practices related to medication adherence. ENABLE thus 90 
considered it important to survey its members on medication management practices during the 91 
pandemic, following deepening concerns that European patients with NCDs may be not receiving 92 
appropriate care or access to essential medicines (WHO, 2020b; Minghui et al., 2020) The aim of this 93 
study was to assess and critically evaluate the medication management practices in place for NCDs 94 
during the second wave of the COVID-19 pandemic across European countries to inform future 95 
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Material and methods 98 
Study design 99 
A cross-sectional, web-based survey was carry out including all the members of ENABLE (i.e. 100 
healthcare providers and academics with medical or pharmaceutical backgrounds) across 38 European 101 
countries (i.e., Albania, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, 102 
Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, 103 
Latvia, Lithuania, Luxemburg, Malta, Moldova, Montenegro, the Netherlands, North Macedonia, 104 
Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey 105 
and the United Kingdom) and one non-European (i.e., Israel) country. The primary outcome of the 106 
survey was a better understanding on the medication management practices for NCDs during the 107 
second wave of COVID-19 across Europe. Ethical approval was not sought as all participants were 108 
ENABLE colleagues reporting publicly available information about their country healthcare systems. 109 
No personal data were stored in relation to this study. All respondents were asked if they wished to be 110 
acknowledged in publications. This study was reported according to the Checklist for Reporting 111 
Results of Internet E-Surveys (CHERRIES) (Eysenbach, 2004). 112 
 113 
Questionnaire development and data collection 114 
First, key elements of the medication management cycle of NCDs were defined by the working group 115 
as a result of extensive discussions (Figure 1). The questionnaire was developed based upon this 116 
framework using following domains: 1) patient and healthcare system regulations, 2) means of 117 
communication between the patient and prescriber, 3) prescriber, 4) prescription, 5) community 118 
pharmacy regulations, 6) medication, and 7) medication taking. A number of questions was generated 119 
for each domain. As part of the validation of the draft questionnaire, seven external experts were asked 120 
to assess each item individually with respect to the content, construct and criterion validity and to offer 121 
their opinions on the overall questionnaire and on the technical functionality of the electronic 122 
questionnaire. Following revision, the final version of the questionnaire contained 33 questions. The 123 
majority of questions were closed with responses: “Yes” / “Partly” / “No” / “Do not know”. 124 
Respondents were instructed to answer “Yes” if the scenario took place in >80% of cases in the given 125 
country, and “Partly” or “No” in 20-80% of cases, and <20% of cases, respectively. The case ratio for 126 
the “Partly” answer was determined based on a consensus discussion by ENABLE collaborators and 127 
was approved by the external experts.  128 
The link to the validated, web-based survey was sent by email to all ENABLE collaborators (n=92, 129 
two or three representatives from each of 39 countries) on December 15th, 2020. The invitation email 130 
informed participants about the purpose of the study, the use and storage of the data and the length of 131 
the survey. The survey was posted on SurveyMonkey.com (www. surveymonkey.com). The online 132 
questionnaire was distributed over 12 pages, with one to five items per page. A copy of the survey can 133 
be seen in Supplementary Figure S1. The average time required to answer the survey was been 134 
estimated at 10 minutes and the respondents were able to review and change their answers before 135 
submitting the survey. This voluntary study was sent personally to ENABLE colleagues so that access 136 
to the questionnaire by non-invited individuals was unlikely. No incentives were offered to ENABLE 137 
collaborators for completing the survey. Respondents were instructed to represent the national 138 
perspective, rather than regional, local or their own perspective; and to provide responses as of 139 
December 2020. The responses should reflect the current measures in place to support treatment of 140 
I  revi
e
 Management of NCDs in Europe during COVID-19 
 
5 
NCDs in the country, regardless of whether they had been introduced following the COVID-19 141 
outbreak or had been in place before the pandemic. The survey was open until December 29th, 2020, 142 
reminders were sent weekly to all participants. 143 
To prevent multiple entries from the same individual, respondents’ names were stored temporarily with 144 
the submitted survey. However, unique user identifiers were eliminated before data analysis. 145 
 146 
Data analysis 147 
A completeness check was conducted after the questionnaire was submitted and only complete 148 
questionnaires (regardless of the time needed for filling the questionnaire) were analysed. Where more 149 
than one complete response was received per country, the responses were aggregated. In the few 150 
instances where answers differed, respondents were contacted to resolve the inconsistencies prior to 151 
data analysis.  152 
In the first step of data analysis, descriptive statistics of the responses were computed. In the next step, 153 
we evaluated the impact of three variables on the solutions available to facilitate continuity of 154 
medication for NCDs during the COVID-19 pandemic. European Centre for Disease Prevention and 155 
Control (ECDC) data were used for the number of COVID-19 cases per 100,000 inhabitants, and the 156 
number of COVID-19 deaths per 100,000 inhabitants in 2020 (ECDC, 2021). Country income was 157 
assessed from World Bank data on gross domestic product (GDP) per capita at purchasing power parity 158 
in current international USD (data from 2019) (World Bank, 2021) (Table 1). Differences in the 159 
number of COVID-19 cases per 100,000 inhabitants (ECDC, 2021), the number of COVID-19 deaths 160 
per 100,000 inhabitants (ECDC, 2021), and GDP per capita data (World Bank, 2021) between “Yes” / 161 
“Partly” / “No” / “Do not know” response groups per each question of the survey were assessed using 162 
Kruskal-Wallis test. A significant Kruskal-Wallis test was followed up by Wilcoxon’s test to calculate 163 
pairwise comparisons between response levels with corrections for multiple testing. Poisson 164 
generalized linear models with log link using robust standard errors were used to assess the association 165 
of the number of teleconsultation approaches (“Yes” and “Partly” response groups were pooled) with 166 
the number of COVID-19 cases per 100,000 inhabitants (ECDC, 2021), the number of COVID-19 167 
deaths per 100,000 inhabitants (ECDC, 2021), and GDP per capita data (World Bank, 2021). The same 168 
analysis was performed for the number of methods for requesting prescriptions for chronic medications 169 
(“Yes” and “Partly” response groups were pooled). In all analyses, P values of < 0.05 were considered 170 
statistically significant. Data management and all statistical analyses were performed using R software 171 
(The R Foundation for Statistical Computing, Vienna, Austria; version 4.0.2). The raw data supporting 172 
the conclusions of this article will be made available by the authors on request, without undue 173 
reservation, to any qualified researcher. 174 
 175 
Results 176 
A total of 53 (58%) of the 92 ENABLE collaborators from 39 countries (12 countries with more than 177 
one respondents) completed the survey. Two-thirds (n=39) of participants' professional background 178 
was academia (i.e., medical or pharmaceutical sciences) and half of respondents (n=26) had more than 179 
20 years of work experience. 180 
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Our results are reported according to the seven key domains of the medication management cycle of 181 
NCDs (Figure 1). Country-specific responses for each item of the survey questionnaire and the detailed 182 
results of the statistical analysis can be found in Supplementary Figure S2-S9 and Supplementary Table 183 
S1-S7, respectively. 184 
 185 
Patient and healthcare system regulations 186 
All the included countries have public healthcare systems available to all citizens. Consultations in 187 
primary healthcare and other ambulatory care are fully or partially covered in all the countries. In 10 188 
(26%) countries there were restrictions in number of consultations without fee in primary care for 189 
patients with NCDs. In these countries the mean number of COVID-19 cases per 100,000 inhabitants 190 
was significantly lower compared to countries with unlimited free primary care consultations (p = 191 
0.017) (Table 2).  192 
In all countries the cost of chronic medications were fully (80%) or partly (20%) reimbursed. The mean 193 
number of COVID-19 cases per 100,000 inhabitants was significantly higher in countries with more 194 
extensive reimbursement for chronic pharmacotherapies (“Yes” response group vs. “Partly” response 195 
group p = 0.004) (Table 2). Electronic prescribing was available in 36 (92%) countries, and it was not 196 
found to be associated with the number of COVID-19 cases and COVID-19 deaths. Furthermore, none 197 
of the evaluated items of the patient and healthcare system regulations domain showed a significant 198 
association with GDP per capita of countries. 199 
 200 
Means of communication between the patient and prescriber 201 
In 35 (90%) of countries, face-to-face primary care and/or out-patient care consultations were, at least 202 
partly, limited due to the COVID-19 pandemic. The number of COVID-19 deaths per 100,000 203 
inhabitants showed an association with the disruption of outpatient care (“Yes” response group / 204 
“Partly” response group vs. “No” response group p = 0.047) (Table 2). The same trend was seen in 205 
case of the number of COVID-19 cases between response groups (p = 0.033); however, in pairwise 206 
comparison this association was not significant anymore (Table 2).  207 
Being able to book an advance appointment for a teleconsultation was available in 33 (85%) countries 208 
and was significantly more common in countries with higher GDP per capita (“Yes” response group 209 
vs. “No” response group p < 0.001, “Partly” response group vs. “No” response group p = 0.036) (Table 210 
2). Across the evaluated countries the mean±SD number of available teleconsultation services (e.g., e-211 
mail, online chat, phone, video, and electronic health records) in the public healthcare system was 212 
3±1.3 (Figure 2A) and it was positively associated with GDP per capita of countries (p = 0.05). 213 
Furthermore, the mean±SD number of teleconsultation methods for requesting prescriptions for 214 
chronic medications was 3.4±1.6 (Figure 2B), but it did not show an association with any of the 215 
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Access to prescribing history and/or dispensing (e.g., within electronic health record) was, at least 219 
partly, available in 33 (85%) countries and only physicians were authorised to prescribe medications 220 
in 22 (56%) countries. These items were not associated with the number of COVID-19 cases, the 221 
number of COVID-19 deaths, or country income.  222 
Prescriptions could be issued during teleconsultations in 32 (82%) countries, significantly more 223 
common in countries with higher GDP per capita (p = 0.006) and in countries with higher number of 224 
COVID-19 cases (p = 0.048) (Table 2). Paper-based repeated drug prescriptions could be sent to the 225 
patient by post only in 9 (23%) countries. The availability of this service was associated with higher 226 
GPD per capita (“Yes” response group vs. “No” response group p = 0.021, “Partly” response group vs. 227 
“No” response group p = 0.001) (Table 2).  228 
Systems to alert the prescribers about the need to renew prescription for chronic treatment were, at 229 
least partly, available only in 11 (28%) countries and it was found to be related to country income when 230 
comparing all response groups (p = 0.028) (Table 2). However, using pairwise comparison the 231 
association was not significant anymore. 232 
 233 
Prescription 234 
To prescribe chronic medications for a more than a 3-months period and when the patient still has a 235 
stock of medication was possible in 26 (67%) and 37 (95%) countries, respectively. Prescribing of 236 
specialist medicines (e.g., high-cost medicines normally prescribed by specialists only) in primary care 237 
during COVID-19 pandemic was, at least partly, allowed in 12 (31%) countries. Regarding the item of 238 
medication prescription when the patient still possesses some medication, the GDP per capita of 239 
countries in the “Yes” response group was significantly higher compared to countries in the “Partly” 240 
response group (p = 0.002) (Table 2). No further association was found between the items of this 241 
domain and the evaluated covariates. 242 
 243 
Community pharmacy regulation 244 
In 26 (67%) countries medication for NCDs could not be dispensed without a prescription. Online 245 
ordering and home delivery of prescription medication without visiting a pharmacy was, at least partly, 246 
available in 18 (46%) and 26 (67%) countries, respectively. Both items showed a positive association 247 
with GDP per capita (online ordering: “Yes” response group vs. “No” response group p = 0.03; home 248 
delivery of prescription medication: “Yes” response group vs. “No” response group p = 0.021). We 249 
also found weak associations between online ordering and the number of COVID-19 deaths per 250 
100,000 inhabitants and between home delivery of prescription medication and the number of COVID-251 
19 cases per 100,000 inhabitants when comparing all response groups; however, none of these 252 
associations remained significant in case of pairwise comparisons (Table 2).  253 
Substitution of unavailable medication was, at least partly, allowed in 33 (85%) countries and 254 
dispensing of specialist medicines (e.g., high-cost medicines normally dispensed by hospitals) by 255 
community pharmacies during COVID-19 pandemic was made, at least partly, possible only in 8 (21%) 256 
countries. These items were not associated with the number of COVID-19 cases, the number of 257 
COVID-19 deaths or country income.  258 
In r vi
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In 35 (90%) countries no reduction of out-of-pocket costs of medication for NCDs was applied during 261 
the COVID-19 pandemic and only 21 (54%) countries applied measures specifically to address 262 
potential shortages of medicines. No significant association was found between the items of this 263 
domain and the evaluated covariates. 264 
 265 
Medication taking 266 
A national policy or specific guidance on ensuring on-going access to medication for NCDs during the 267 
COVID-19 pandemic was issued in 20 (51%) countries. In case of this variable, differences in the 268 
number of COVID-19 cases per 100,000 inhabitants between response groups were found to be 269 
significant with Kruskal-Wallis test (p = 0.034); however, in the pairwise comparison it was not 270 
significant anymore (Table 2).  271 
Special initiatives for maintaining chronic pharmacotherapies were introduced in 20 (51%) countries, 272 
which was weakly associated with the number of COVID-19 deaths (p = 0.039), but this association 273 
did not remain significant in case of pairwise comparison (Table 2). 274 
 275 
Discussion 276 
Our study offers a comprehensive ‘snapshot’ of how different European countries responded to the 277 
challenge of assuring medication management services for NCDs during the second wave of the 278 
COVID-19 pandemic. In only half of European countries were our respondents aware of any national 279 
guidelines regarding strategies for maintaining medication availability for people with NCDs, or advice 280 
for patients on how to ensure access to medication and adherence during the pandemic. Apart from a 281 
widespread switch to remote consulting, the use of e-health solutions was variable. Electronic 282 
prescriptions were available in 92% of countries, whereas online ordering and home delivery of 283 
prescription medication were only available 46% and 67% of countries, respectively.  284 
In line with the results of the WHO survey (WHO, 2020b), and a global survey of healthcare 285 
professionals (Chudasama et al., 2020), our findings highlight that the COVID-19 pandemic limited 286 
the number of face-to-face appointments for NCDs in primary care, and out-patients. Medication 287 
management of NCDs during the COVID-19 pandemic varied between countries, which was partly 288 
explained by the differences in the structure and financing of healthcare systems across Europe. In 289 
general, greater disruption in healthcare and accelerated the uptake of e-health services was associated 290 
with greater burden of COVID-19 (Table 2). However, typically various e-health solutions were not 291 
merged into a seamless system and there may have been substantial variations even within countries. 292 
For example, in more than 80% of countries, prescriptions for NCDs could be issued without a face-293 
to-face consultation; but home delivery of prescription medications was not available in 13 countries. 294 
In these countries, despite the availability of telemedicine services and electronic prescription, patients 295 
with NCDs could still not get their medications without leaving home. Especially in the more 296 
vulnerable patients who were shielding, it would be important to reduce the number of unnecessary 297 
personal contacts in order to reduce risk.  298 
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The COVID-19 pandemic promoted the use of e-health technologies as social distancing prevented 299 
traditional face-to-face patient-physician appointments. The available forms of teleconsultations, and 300 
options for requesting medication prescriptions were different across the evaluated countries (Figure 301 
2). In the majority of countries, phone and e-mail were the most commonly used modes of digital 302 
communication between patients and physicians. However, in countries with higher GDP per capita, a 303 
wider range of teleconsultation (e.g., online chat, video-consultations, communication via the 304 
electronic health record portal) and e-health services (e.g., alerts when prescriptions need to be 305 
renewed, online ordering of prescription medication) were available for the management of patients 306 
with NCDs (Table 2). These results highlight the potential of innovative models of care to meet the 307 
challenges of the pandemic (Gunasekeran et al., 2021). An example of such a solution could be an 308 
alerting system for prescribers about the need to renew prescriptions for chronic treatment, reported in 309 
11 countries. However, even simple solutions are worth introducing, in order to make the NCD patient 310 
journey easier, such as the possibility of advance scheduling of teleconsultations (missing in 6 311 
countries). 312 
Evidence suggests that the out-of-pocket cost of drugs is a significant determinant of medication 313 
adherence (Dodd et al., 2018) and a few countries reduced medication costs to offset the economic 314 
disruption of the COVID-19 pandemic. Inability to afford drugs increases the risk of non-adherence 315 
and non-persistence to chronic treatments. Allowing longer-duration prescriptions could facilitate 316 
access to drug supplies especially for patients living in remote areas, though this needs to be balanced 317 
against the risk of supply problems with ‘stockpiling’ during the COVID-19 lockdown. Substituting 318 
unavailable medicines by a pharmacist could be a practical solution to medicine shortages. The 319 
medication supply chain is being strained by the pandemic (Shuman et al., 2020); nevertheless, only 320 
54% of countries reported measures specifically to address potential shortages of medicines. In addition 321 
policy interventions to improve drug coverage and behavioural support consisting in patient education 322 
can improve medication adherence among people with chronic diseases (Viswanathan et al., 2012). 323 
The reduction in the number of face-to-face appointments, and the lack or low number of interventions 324 
assuring continuous treatment of NCDs (e.g. the absence of systems to alert prescribers about the need 325 
to renew prescriptions) during the pandemic may have significant clinical consequences. This also 326 
makes economic sense as medication non-adherence leads to higher health care use and costs despite 327 
decreased drug spending (Roebuck et al., 2011). Nevertheless, half of our respondents were unaware 328 
of any national guidelines for preserving medication supplies NCDs or for patients on how to access 329 
medication and maintain adherence during the COVID-19 pandemic. These findings suggest that there 330 
is room for a system-based approach to ensure the maintenance of treatments for NCDs during crises 331 
(such as pandemics) to minimise the consequences on long-term condition care. A European Union 332 
vision of resilient healthcare following the COVID-19 pandemic includes strengthening primary care 333 
and mental healthcare (EXPH, 2020), bringing some hope that this ambition will become a reality. 334 
Further studies are warranted to improve understanding of the long-term clinical and economic 335 
consequences of the disruption to NCD services during the COVID-19 pandemic. 336 
Our survey highlights major disparities in the way different European countries are dealing with the 337 
challenge of managing NCDs during the COVID-19 pandemic, and suggests strategies for 338 
improvement. Several practical and low-cost solutions (Figure 1) could be applied, as suggested in our 339 
quick commentary (Kardas et al., 2021), including: (1) an increased range of remote services for 340 
ordering repeat prescriptions (e.g., online, via mobile app), (2) expanding the scope of professionals 341 
authorised to prescribe (or issue repeat prescriptions), (3) increasing the duration of prescriptions 342 
(though this needs to be balanced with managing shortages), (4) enabling community pharmacies to 343 
dispense medications normally restricted to hospitals, (5) allowing substitution of unavailable drugs, 344 
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(6) creating e-health systems supporting patients in long-term treatment, encouraging patient 345 
empowerment and patient-centred care, and (7) providing publicly available guidance on strategies for 346 
maintaining treatment during pandemic lockdown. Our findings point to interventions worth taking 347 
during COVID-19 pandemic in order to maintain NCDs treatment. It might be hypothesized; however, 348 
that these activities are also important beyond the current pandemic, as healthcare systems adapt to an 349 
ageing population with increasing multimorbidity (Chatterji et al., 2015; WHO, 2018b).  350 
Our results should be considered in light of the following limitations. The self-developed questionnaire 351 
and multiple-choice questions with closed answers allowed us to seek very specific information; 352 
however, it may be biased by the authors’ preconceived perceptions. To minimize this risk, external 353 
experts were asked to assess the questionnaire with respect to the content, construct and criterion 354 
validity. The survey was completed by members of ENABLE who were asked to provide information 355 
on the current practices in their own countries rather than regional, local or their own perspective. In 356 
12 countries we had more than one respondent; however, in some countries information was based on 357 
the answers of one respondent, which might lead to bias. The majority of participants were working at 358 
the academic sector of medical or pharmaceutical sciences with more than 20 years of work experience, 359 
and their views represents one perspective while there may be substantial differences in primary 360 
healthcare and medicines even between regions within a country. It should also be noted that the 361 
regulations and reimbursement of primary care and pharmacy practice are changing over time, and 362 
especially digital solutions were rapidly introduced in healthcare in many countries already before the 363 
COVID-19 outbreak. Consequently, this survey represents the situation at a single point of time and 364 
the replies for some questions may have differed substantially if the survey had been distributed at 365 
another time point.  366 
To conclude, our survey has identified marked disparities in ensuring medication management services 367 
for NCDs across Europe. This points to the need for a paradigm shift in NCD-related healthcare 368 
services to assure access and enable adherence to chronic pharmacotherapies during the current 369 
pandemic (and future disasters). E-health solutions cannot solve all the challenges of NCD care (e.g 370 
some therapies need regular blood tests) and safe arrangements will be needed. In the short-term, we 371 
must optimise the health of NCD patients at risk of poor outcomes from COVID-19. In the long-term, 372 
maintaining access to NCD treatments could limit the negative consequences of disruptive health 373 
service events. 374 
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Table 1. Country specific population size, GDP per capita and COVID-19 burden data  499 
Country 
Population size, 2020 
[Eurostat, 2021; 
ECDC, 2021]] 
GDP per capita, 
PPP, 2019 (current 
international USD) 
[Word Bank, 2021] 
N of COVID-19 cases 
per 100,000 
inhabitants in 2020 
[ECDC, 2021] 
N of COVID-19 
deaths per 100,000 
inhabitants in 2020 
[ECDC, 2021] 
Albania 2,862,427  14,648.3  2,076  42  
Austria 8,858,775  60,418.0  4,115  71  
Belgium 11,455,519  56,348.5  5,681  172  
Bosnia and 
Herzegovina 
3,280,815  16,288.8  3,433  126  
Bulgaria 7,000,039  25,312.1  2,901  110  
Croatia 4,076,246  31,130.8  5,224  100  
Cyprus 875,899  41,254.4  2,737  15  
Czechia 10,649,800  44,295.9  7,012  113  
Denmark 5,806,081  62,089.9  2,906  24  
Estonia 1,324,820  39,986.2  2,228  19  
Finland 5,517,919  53,171.6  669  10  
France 67,012,883  50,993.0  3,963  97  
Germany 83,019,213  57,530.3  2,139  42  
Greece 10,724,599  32,506.4  1,306  46  
Hungary 9,772,756  34,966.3  3,365  102  
Iceland 356,991  60,132.5  1,612  8  
Ireland 4,904,240  89,683.6  2,078  46  
Israel 8,655,541  42,897.8  5,109  40  
Italy 60,359,546  45,722.6  3,571  125  
Latvia 1,919,968  33,020.8  2,213  35  
Lithuania 2,794,184  40,016.3  5,297  49  
Luxembourg 613,894  124,590.5  7,643  82  
Malta 493,559  47,578.2  2,651  45  
Moldova 4,033,963  13,627.0  3,616  75  
Montenegro 622,182  24,035.9  7,907  111  
Netherlands 17,282,163  61,285.0  4,746  67  
North 
Macedonia 
2,077,132  18,107.8  4,045  122  
Norway 5,328,212  70,005.9  952  8  
Poland 37,972,812  35,165.2  3,484  77  
Portugal 10,276,617  37,918.4  4,158  69  
Romania 19,414,458  33,339.9  3,299  82  
Serbia 6,963,764  19,495.1  4,938  48  
Slovakia 5,450,421  33,515.9  3,451  46  
Slovenia 2,080,908  42,431.2  6,048  139  
Spain 46,937,060  43,495.9  4,173  109  
Sweden 10,230,185  56,632.1  4,592  88  
Switzerland 8,544,527  72,376.0  5,380  85  
Turkey 82,003,882  28,133.1  1,729  26  
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66,647,112  49,931.6  3,983  113  
GDP: gross domestic product; PPP: purchasing power parity 500 
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Table 2. Significant results of the statistical analysis on the association between the number of COVID-19 cases and deaths per 100,000 501 
inhabitants and GDP per capita and the evaluated items of the medication management of NCDs  502 
 
Yes Partly No 
P-value 
Kruskal-Wallis test (Wilcoxon test - 
pairwise comparison) 
Number of COVID-19 cases per 100,000 inhabitants in 2020, mean ± SD 
Q8 Unlimited number of consultations with primary care is available to patients 
with chronic conditions without any fee 
4127.5 ± 
1653.0 
NA 2673.3 ± 
1558.1 
0.017 
Q9 Chronic medications are a subject of reimbursement (i.e. either patients do not 






Q11 Face-to-face primary care and/or ambulatory specialist care appointments are 








(“Yes” / “Partly” vs “No” = 0.061; 
“Yes” vs. “Partly” = 0.141) 







(“Yes” / “Partly” vs “No” = 0.048; 
“Yes” vs. “Partly” = 0.579) 









( “Yes” vs “No” = 0.579; “Partly” 
vs “No” = 0.066; “Yes” vs. “Partly” 
= 0.066) 
Q30 Publicly available guidance for patients / repositories of  information advising 
how to maintain chronic treatment during COVID-19, have been issued by, or 








(“Yes” / “Partly” vs “No”  = 0.053; 
“Yes” vs. “Partly” = 0.97) 
Number of COVID-19 deaths per 100,000 inhabitants in 2020, mean ± SD 
Q11 Face-to-face primary care and/or ambulatory specialist care appointments are 
limited due to COVID-19 
73.2 ± 41.9 82.0 ± 37.7 23.0 ± 17.0 0.059  
( “Yes” / “Partly” vs “No” = 0.047; 
“Yes” vs. “Partly” = 0.440) 
Q24 Online ordering of prescription medication (i.e. medication available 
according to prescription only) is possible 
60.9 ± 37.4 32.8 ± 37 84.3 ± 40 0.05  
( “Yes” vs “No” = 0.14; “Partly” vs 
“No” = 0.12; “Yes” vs. “Partly” = 
0.25) 
Q31 Special initiatives aimed at maintenance of chronic treatment during COVID-
19 have been introduced 
77.4 ± 35.0 92.5 ± 29.0 51.4 ± 38.2 0.039  
(“Yes” vs “No” = 0.102; “Partly” vs 
“No” = 0.074; “Yes” vs. “Partly” = 
0.343) 
GDP per capita, PPP, 2019 (current international USD), mean ± SD 
Q12 Teleconsultations are subject of advance scheduling (e.g. you may schedule 








( “Yes” vs “No” <0.001; “Partly” vs 
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(“Yes” vs “No” = 0.023; “Partly” vs 
“No” = 1; “Yes” vs. “Partly” = 
0.039) 







(“Yes” vs “No” = 0.021; “Partly” vs 
“No” = 0.001; “Yes” vs. “Partly” = 
0.905) 
Q19 Alerting systems are available to alert the prescribers about the need to renew 








(“Yes” / “Partly” vs “No” = 0.074; 
“Yes” vs. “Partly” = 0.662) 




47578.2  0.005  
(“Yes” vs “No” = 0.929; “Partly” vs 
“No” = 0.545; “Yes” vs. “Partly” = 
0.002) 
Q24 Online ordering of prescription medication (i.e. medication available 








(“Yes” vs “No” = 0.03;“Partly” vs 
“No” = 1; “Yes” vs. “Partly” = 
0.54) 









(“Yes” vs “No” = 0.021; “Partly” vs 
“No” = 0.880; “Yes” vs. “Partly” = 
0.018) 
GDP: gross domestic product; NA: not applicable; PPP: purchasing power parity; SD: standard deviation503 
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Figure legends 504 
Figure 1. Medication management cycle and interventions that could help continuous 505 
pharmacological management of non-communicable diseases 506 
 507 
Figure 2. Availability of various forms of teleconsultations (A), and options for requesting chronic 508 
medication prescriptions (B) across 39 European countries, as per December 2020 509 
 VC: videoconsultation; EHR: electronic health record  510 
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